Arkstone published new peer-reviewed data on OneChoice in Diagnostics, showing that when an infectious disease specialist looks at a urinary tract infection case, OneChoice reaches the same call they would compared to generalist physicians in Lima Peru.
Public source
Publisher name
Public post
New peer-reviewed data on OneChoice, published in Diagnostics. We asked a simple question. When an infectious disease specialist looks at a urinary tract infection case,…
Company
Arkstone
Empowering the healthcare community with innovative tools to help reduce the global threat of antimicrobial resistance
- Industry
- Biotechnology Research
- Location
- Durham, US
- Company size
- 11–50 employees
About Arkstone
The only technology capable of analyzing source of specimen, diagnosis, organisms, resistance genes, allergies, age and gender. The Arkstone lab report is the most comprehensive and advanced antimicrobial stewardship program available.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
iFAST Diagnostics
iFAST Diagnostics published a peer-reviewed paper in the Journal of Clinical Microbiology titled “Multisite clinical evaluation of the iFAST rapid antimicrobial susceptibility test direct from positive blood cultures containing gram-negative organisms”
Research & Knowledge
Cytovale
Cytovale published a full breakdown of 30,000 unnecessary hospital days hiding in a sepsis workflow found by a health system.
Research & Knowledge
Resistome Clinical Services
Resistome Clinical Services published an article examining S. aureus bacteremia through a simple framework of detection, interpretation, decision, and clinical resolution.
Research & Knowledge
Delve Bio
Delve Bio published findings in the Nature Medicine publication showing that Delve Detect outperformed conventional diagnostic testing methods for CNS infections.
Research & Knowledge
MicroGenDX